Biotech · Private company
ThromboGenics
Track this companyFree. Adds ThromboGenics to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- ocriplasmin 0.0625mgPhase 2 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- ocriplasmin 0.125mgPhase 2 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Sham injectionPhase 2 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- THR-149 dose level 1Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- THR-149 dose level 2Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- THR-149 dose level 3Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- THR-687 dose level 1Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- THR-687 dose level 2Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- THR-687 dose level 3Phase 1 · Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)PHASE1 · COMPLETED · started Sep 17, 2018ClinicalTrials.gov NCT03666923 · fetched Nov 12, 2026
- A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)PHASE1 · COMPLETED · started May 18, 2018ClinicalTrials.gov NCT03511898 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDRPHASE2 · TERMINATED · started Dec 1, 2015ClinicalTrials.gov NCT02681809 · fetched Nov 12, 2026